Recent studies have revealed an important role for the enzyme phospholipase A2 (PLA2) in various aspects of inflammation in the peripheral and central nervous system. PLA2 consists of a superfamily of enzymes involved in the turnover of phospholipids; their metabolic products can induce both inflammation and demyelination. Therefore, PLA2 enzymes are good candidates as drug targets for the treatment.
UC San Diego researchers have developed novel amide compounds for the treatment of inflammation. The new molecules are potent inhibitors of secreted PLA2 (sPLA2).
This technology is offered exclusively or nonexclusively in the U.S. and/or worldwide territories. A commercial sponsor for potential future research is sought.
|United States Of America||Issued Patent||8,759,392||06/24/2014||2009-002|
therapy, drug, phospholipase A2, PLA2, inhibitor, inflammation, demyelination